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Azimilide Reduces Emergency
Department Visits and Hospitalizations
in Patients With an Implantable Cardioverter-
Defibrillator in a Placebo-Controlled Clinical Trial
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Stefan H. Hohnloser, MD, FACC,‡ Jose M. Brum, MD, MSC,† Preston M. Dunnmon, MD, FACC,†
Craig M. Pratt, MD, FACC,§ Michael J. Holroyde, PHD,† Peter Kowey, MD, FACC,
on behalf of the SHIELD (SHock Inhibition Evaluation with AzimiLiDe) Investigators
Toronto, Ontario, Canada; Cincinnati, Ohio; Frankfurt, Germany; Houston, Texas;
and Philadelphia, Pennsylvania
Objectives The goal of this study was to determine whether azimilide, as compared with placebo, will reduce the number of
emergency department (ED) visits and hospitalizations caused by arrhythmias or cardiac events in patients with
an implantable cardioverter-defibrillator (ICD).
Background Patients with an ICD may require ED visits and hospitalizations because of arrhythmias, which trigger ICD thera-
pies. The effect of adjunctive antiarrhythmic therapy on these outcomes is not known.
Methods A total of 633 patients with an ICD were randomized in the SHIELD (SHock Inhibition Evaluation with AzimiLiDe)
trial, a blinded, placebo-controlled randomized trial of the investigational class III antiarrhythmic azimilide (75
and 125 mg/day), and, prospectively, cardiac and arrhythmic ED visits and hospitalization data were collected
over 1 year.
Results All patients had symptomatic sustained ventricular tachycardia (72%) or ventricular fibrillation (28%) before
study entry. Overall, 44% (n  276) experienced at least 1 cardiac ED visit or hospitalization. Among 214 pa-
tients assigned to placebo, 38.3% had at least 1 arrhythmic-related ED visit or hospitalization compared with
21.8% of 220 patients assigned to 75-mg azimilide (p  0.001) and 27.6% of 199 patients assigned to 125 mg
azimilide (p  0.05). Symptomatic ventricular tachycardia treated by antitachycardia pacing, shocks, and shocks
plus symptomatic arrhythmias were significant predictors of cardiac-related ED visits or hospitalizations (relative
risk: 2.0, 3.0, and 3.1, respectively). In a stepwise logistic regression model, the presence of congestive heart
failure (New York Heart Association functional class II/III) was the only additional independent predictor of car-
diac ED visits or hospitalizations.
Conclusions Azimilide significantly reduces the number of ED visits and hospitalizations in patients with an ICD at high risk of
arrhythmias. (J Am Coll Cardiol 2008;52:1076–83) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.055u
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Bmplantable cardioverter-defibrillators (ICDs) reduce mor-
ality, compared with standard medical therapy alone, when
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sed for primary (1,2) or secondary (3) prophylaxis of
udden death in patients at risk for life-threatening ventric-
From the Division of Cardiology, St. Michael’s Hospital/University of Toronto,
oronto, Ontario, Canada; †Health Care Research Center, Procter & Gamble Pharma-
euticals, Cincinnati, Ohio; ‡Department of Cardiology, Division of Electrophysiology,
.W. Goethe-University, Frankfurt, Germany; §Methodist DeBakey Heart Center,ouston, Texas; and the Division of Cardiovascular Diseases, Jefferson Medical College,
hiladelphia, Pennsylvania. This study was supported by Procter & Gamble Pharmaceuticals, alar arrhythmias. However, many patients with an ICD
ventually experience multiple arrhythmic events, often
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ent of ventricular arrhythmias are often evaluated in an
mergency setting and hospitalized for stabilization of heart
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September 23, 2008:1076–83 Azimilide Reduces Hospitalization in ICD Patientsailure, to rule out myocardial infarction (MI) or ischemia,
r for other investigations. Patients who experience these
ecurrent events also often receive additional antiarrhythmic
herapy with drugs such as sotalol or amiodarone since there
s evidence that these agents decrease the number of ICD
herapies (5,6). In addition to benefits from adjunctive
ntiarrhythmic therapy on symptoms and quality of life,
ntiarrhythmic therapy that reduces recurrent events, par-
icularly clusters of ventricular tachycardia (VT) or ventric-
lar fibrillation (VF), may be expected to reduce health care
esource consumption. However, the effect of antiarrhyth-
ic therapy on the number and duration of hospitalizations
n patients with an ICD has not been systematically inves-
igated in a controlled clinical trial.
Azimilide dihydrochloride is an investigational class III
ntiarrhythmic drug that was evaluated in a randomized,
ouble-blind, placebo-controlled study (SHIELD [SHock
nhibition Evaluation with AzimiLiDe]) to test the safety
nd efficacy of daily doses of azimilide in patients with an
CD and a documented history of sustained VT, VF, or
ardiac arrest. In the SHIELD study, the 75-mg dose of
zimilide significantly reduced the recurrence of shocks plus
ymptomatic arrhythmias treated by ATP, as well as ar-
hythmic storms (7). This study assessed the effects of
zimilide treatment on the pre-specified end points of
mergency department (ED) visits and hospitalizations in
atients with an ICD enrolled in the SHIELD trial.
ethods
atient population. The SHIELD trial was a randomized
linical study undertaken at 121 sites in 9 countries (U.S.,
anada, Germany, Poland, France, Spain, Netherlands,
elgium, and Italy). The study design and the primary
esults have been reported in detail (7). The study complied
ith the Declaration of Helsinki. The locally appointed
thics committee approved the research protocol, and sub-
ects provided informed consent.
In brief, patients were eligible if they had a documented
pisode of spontaneous sustained VT or VF (with an
jection fraction [EF] of 40% for the latter group) during
he 42 days preceding a first ICD implantation or had a
re-existing ICD implant and then received an ICD shock
riggered by spontaneous VT or VF.
Patients were excluded if they had New York Heart
ssociation (NYHA) functional class IV heart failure;
nstable angina; or recent (within 30 days) MI, prolonged
Tc intervals at baseline (440 ms, with a QRS120 ms),
r JTc (320 ms with a QRS 120 ms); or major cardiac
r noncardiac illness that would limit survival. Antiarrhyth-
ic drugs were stopped at least 5 half-lives before study
rug dosing or at least for 60 days in case of prior chronic
miodarone therapy.
ICDs were programmed according to a strictly defined
rotocol, with the “floor” for VT detection specified accord-
ng to the slowest documented VT rate, and a ceiling set at f00 beats/min. For patients with
ual-chamber ICDs, at least 1
T discriminator was enabled.
TP was programmed “on” in all
atients, with a minimum of 2
ttempts in the lowest detection
one, followed by shocks if nec-
ssary. Above 200 beats/min,
nly shock therapies were pro-
rammed.
tudy protocol. Randomization
as conducted in a ratio of 1:1:1
o placebo or 2 doses of azimilide
75 or 125 mg once daily). Pa-
ients were stratified within a
eographic region by beta-
locker usage, left ventricular EF
40% or 40%) and ICD
type” (existing or new ICD).
atients were followed and
aintained on the originally as-
igned blinded therapy for 365 days (unless withdrawn for
ny reason), regardless of the number of intervening ar-
hythmia events. In this study, ED visits and hospitalization
ata, including numbers of selected in-hospital treatments
nd procedures were pre-specified end points with case-
eport forms designed to prospectively collect cardiac (ar-
hythmic and nonarrhythmic)-related events during the
linded phase of the study. Adverse events were systemat-
cally collected using standard COding Symbols for a
hesaurus of Adverse Reaction Terms for adverse events.
tatistical analysis. Continuous baseline characteristics are
resented as mean  SD and were compared among the
roups using the Wilcoxon rank sum test. Group compar-
sons of categorical data were conducted using Pearson’s
hi-square test. The ED visits and hospitalization data were
nalyzed using time-to-event analysis. The survival curves
ere generated using Kaplan-Meier estimates, and the
og-rank statistic was used to assess the statistical signifi-
ance of the observed treatment differences in the time-to-
vent distribution. The Cox proportional hazard model was
sed to estimate the hazard ratio (HR) and the 95%
onfidence interval for the azimilide group to the placebo
roup. The Andersen-Gill mean intensity model (8) was
sed to analyze recurrent (i.e., multiple) ED visits and
ospitalizations. This model produces a robust variance for
he estimated parameter (treatment effect) and thus adjusts
or the correlation between recurrent events within a pa-
ient. The Andersen-Gill mean intensity model is a gener-
lization of Cox’s proportional hazards model (9) (i.e., if
nly the first event is considered, then this model is
quivalent to Cox’s model). In addition, an estimated mean
unction (Nelson-Aalen estimator) (10) was calculated to
escribe recurrent events over time between treatment
roups. This estimator is a simple nonparametric estimator
Abbreviations
and Acronyms
ATP  antitachycardia
pacing
CHF  congestive heart
failure
ED  emergency
department
EF  ejection fraction
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
MI  myocardial infarction
NYHA  New York Heart
Association
TdP  torsades de pointes
VF  ventricular fibrillation
VT  ventricular
tachycardiaor the cumulative hazard over time for recurrent events (it
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Azimilide Reduces Hospitalization in ICD Patients September 23, 2008:1076–83s an analog to the Kaplan-Meier estimator in the single
vent case). The plot of these estimators demonstrates
hether the expected number of events is significantly
ifferent among treatment groups.
All the statistical analyses were performed using SAS
tatistical software, version 9.1 procedure PHREG (SAS
nstitute, Cary, North Carolina) in which ties were handled
y the method of exact likelihood. A 2-sided p value 0.05
as considered significant.
esults
total of 633 patients were randomized to placebo (n 
14), 75-mg (n  220), and 125-mg azimilide (n  199).
aseline characteristics and concomitant drug therapy for
hose with at least 1 ED visit or hospitalization and those
ith no ED visits or hospitalization are shown in Table 1.
Overall, 44% experienced at least 1 cardiac ED visit or
ospitalization. The total number of cardiac-related ED
isits or hospitalizations for the placebo, 75-mg azimilide,
nd 125-mg azimilide groups was 211, 121, and 150,
espectively, and the total arrhythmic-related ED visits or
ospitalizations was 120, 63, and 71, respectively. Table 2
hows that treatment with 75-mg azimilide significantly
educes both cardiac- and arrhythmic-related ED visits or
ospitalizations with relative risk reductions of 37% (log-
ank p  0.002) and 47% (log-rank p  0.0004), respec-
ively. Additionally, treatment with 125-mg azimilide sig-
aseline Characteristics and Concomitant Medication
Table 1 Baseline Characteristics and Concomitant Medication
Hospitalized
Category
Azimilide
(N  166)
Placebo
(N  110)
Age (yrs), mean (SD) 65 (11.13) 64.5 (10.07)
Ejection fraction (%), mean (SD)* 31.8 (11.65) 30.4 (12.64)
CHF, NYHA functional class
I 21 (12.7%) 15 (13.6%)
II 79 (47.6%) 51 (46.4%)
III* 26 (15.7%) 15 (13.6%)
Other cardiovascular characteristics
Atrial fibrillation* 67 (40.4%) 47 (42.7%)
Myocardial infarction 106 (63.9%) 69 (62.7%)
ICD indication
Cardiac arrest 1 (0.6%) 0 (0.0%)
VF 53 (31.9%) 29 (26.4%)
VT 112 (67.5%) 81 (73.6%)
Diabetes 39 (23.5%) 25 (22.7%)
Concomitant medications
ACE 129 (77.7%) 82 (74.5%)
Aspirin 72 (43.4%) 45 (40.9%)
Beta-blockers 142 (85.5%) 99 (90.0%)
Digoxin* 76 (45.8%) 50 (45.5%)
Diuretics* 117 (70.5%) 87 (79.1%)
Spironolactone* 29 (17.5%) 24 (21.8%)
Statins 91 (54.8%) 63 (57.3%)
alues are n (% of patients in category and treatment group). *p  0.05 (overall category compa
ACE  angiotensin-converting enzyme; CHF  congestive heart failure; ICD  implantable cardioverte
F  ventricular fibrillation; VT  ventricular tachycardia.ificantly reduced arrhythmic-related ED visits or
ospitalizations with a relative risk reduction of 31% (log-
ank p  0.032). By the Kaplan-Meier estimate over 1 year
Fig. 1), 383 of 1,000 patients with an ICD assigned to
lacebo will have a visit to the ED or will be hospitalized 1
r more times due to an arrhythmic event, whereas only 218
f 1,000 patients assigned to 75-mg azimilide will experi-
nce these events (i.e., number needed to treat to prevent 1
uch event per year  6) (Table 2).
In addition, using the Andersen-Gill mean intensity
odel, recurrent cardiac ED visits or hospitalizations (i.e.,
aking into account both the first occurrence of ED visit or
ospitalization and the subsequent admissions, correcting
or unequal distribution between patients) were reduced
mong patients treated with 75-mg azimilide by 46%
p  0.001) as compared with that seen in placebo-assigned
atients (Fig. 2).
Among patients experiencing an ED visit or hospitaliza-
ion, the majority of the events involved hospitalization.
mong 276 patients with at least 1 cardiac ED visit or
ospitalization, only 76 (27.5%) experienced at least 1 ED
isit: 35 patients assigned to placebo, 18 patients assigned to
5 mg azimilide, and 23 patients assigned to 125 mg
zimilide. Device-treated arrhythmias were strong predica-
ors of hospitalization. Patients experiencing only symptom-
tic arrhythmias terminated by ATP (but no shocks), shocks
nly, and both shocks and symptomatic arrhythmias termi-
Not Hospitalized
Overall
(N  276)
Azimilide
(N  253)
Placebo
(N  104)
Overall
(N  357)
64.8 (10.72) 64.5 (11.21) 63.3 (12.27) 64.1 (11.53)
31.2 (12.07) 34 (12.89) 33.7 (13.56) 33.9 (13.08)
36 (13.0%) 36 (14.2%) 21 (20.2%) 57 (16.0%)
130 (47.1%) 105 (41.5%) 40 (38.5%) 145 (40.6%)
41 (14.9%) 18 (7.1%) 5 (4.8%) 23 (6.4%)
114 (41.3%) 68 (26.9%) 35 (33.7%) 103 (28.9%)
175 (63.4%) 159 (62.8%) 72 (69.2%) 231 (64.7%)
1 (0.4%) 4 (1.6%) 0 (0.0%) 4 (1.1%)
82 (29.7%) 60 (23.7%) 30 (28.8%) 90 (25.2%)
193 (69.9%) 187 (73.9%) 74 (71.2%) 261 (73.1%)
64 (23.2%) 32 (12.6%) 23 (22.1%) 55 (15.4%)
211 (76.4%) 184 (72.7%) 77 (74.0%) 261 (73.1%)
117 (42.4%) 96 (37.9%) 45 (43.3%) 141 (39.5%)
241 (87.3%) 214 (84.6%) 87 (83.7%) 301 (84.3%)
126 (45.7%) 81 (32.0%) 30 (28.8%) 111 (31.1%)
204 (73.9%) 142 (56.1%) 44 (42.3%) 186 (52.1%)
53 (19.2%) 31 (12.3%) 7 (6.7%) 38 (10.6%)
154 (55.8%) 157 (62.1%) 65 (62.5%) 222 (62.2%)
etween hospitalized and not hospitalized).risons b
r-defibrillator; N  number of patients in treatment group; NYHA  New York Heart Association;
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September 23, 2008:1076–83 Azimilide Reduces Hospitalization in ICD Patientsated by ATP all had a significantly increased risk for a
ardiac-related ED visit or hospitalization compared with
atients without arrhythmias, with relative risks of 2.0, 3.0,
nd 3.1, respectively (Table 3). In addition, patients expe-
iencing only symptomatic arrhythmias terminated by ATP,
hocks only, and both shocks and symptomatic arrhythmias
erminated by ATP had a significantly increased risk for an
rrhythmic-related ED visit or hospitalization compared
ith patients without arrhythmias with a relative risk of 4.2,
.8, and 9.9, respectively. Figure 3 illustrates the cumulative
ncidence of arrhythmic-related ED visits and hospitaliza-
ions in patients with no appropriate ICD therapies due to
ymptomatic arrhythmias, therapies for isolated arrhythmic
vents, and therapies for electrical storms (defined as 3
ppropriate therapies in 24 h [5]). Of the 339 patients who
xperienced symptomatic arrhythmias (treated with shocks
nd/or ATP), 195 (58%) patients required a hospital visit.
f these 195 patients, 150 (77%) required a hospitalization
ithin 24 h of their arrhythmic event. In these patients,
5-mg azimilide reduced cardiac-related ED visits or hos-
italization occurring within 24 h of arrhythmic events by
8%. There were 137 patients with at least 1 nonarrhythmic-
elated ED visit or hospitalization (50 in placebo, 41 in
Figure 1 Kaplan-Meier Cumulative Incidence of Cardiac
Arrhythmic-Related ED Visits and Hospitalizations
AZ  azimilide; ED  emergency department; RRR  relative risk reduction.
umulative Incidence of Cardiac and Arrhythmic-Related ED Visits
Table 2 Cumulative Incidence of Cardiac and Arrhythmic-Relate
End Point Treatment N n (%)
All cardiac-related ED/hospitalization
Placebo 214 110 (51.4%)
Azimilide 75 mg 220 77 (35.0%)
Azimilide 125 mg 199 89 (44.7%)
Arrhythmic-related ED/hospitalization
Placebo 214 82 (38.3%)
Azimilide 75 mg 220 48 (21.8%)
Azimilide 125 mg 199 55 (27.6%)
I  confidence interval; ED  emergency department; N  number of patients in treatment gro5-mg azimilide, and 46 in 125-mg azimilide) who expe-
ienced a total of 228 nonarrhythmic-related ED visits or
ospitalizations (91 in placebo, 58 in 75-mg azimilide, and
9 in 125-mg azimilide). The comparison between 75-mg
zimilide and placebo was statistically significant (HR: 0.57,
5% confidence interval: 0.37 to 0.90; p 0.0145) using the
ndersen-Gill mean intensity model.
In a stepwise multivariate logistic regression model con-
rolling for treatment and other relevant risk factors (gender,
ge 65 years vs. 65 years, EF 35% vs. 35%, conges-
ive heart failure [CHF], previous MI, new or existing ICD,
nd beta-blocker usage), only the presence of CHF (NYHA
unctional class II/III) was an independent predictor of
ardiac ED visits and hospitalizations.
Hospitalizations due to CHF were recorded on the
dverse events log; among 48 patients who were hospitalized
t least once due to CHF (22 in placebo, 11 in 75-mg
zimilide, and 15 in 125-mg azimilide), there were a total of
1 hospitalizations (27 in placebo, 14 in 75-mg azimilide,
nd 20 in 125-mg azimilide). The CHF hospitalization
omparison between 75-mg azimilide and placebo was
tatistically significant (p  0.05, Fisher exact test).
spitalizations
Visits or Hospitalizations
l ED Visits and
spitalizations Hazard Ratio 95% CI
Log-Rank
p Value
211
121 0.63 (0.47–0.85) 0.0020
150 0.85 (0.64–1.13) 0.2535
120
63 0.53 (0.37–0.76) 0.0004
71 0.69 (0.49–0.97) 0.0320
)  number and percentage of patients in category and treatment group.
Figure 2 Cumulative Risk of Recurrent Cardiac-Related ED Vis-
its or Hospitalizations Over Time by Treatment Group
The slope of each curve represents the estimated rate of total cardiac-
related ED visits or hospitalizations within each group. Abbreviations as in Figure 1.or Ho
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Azimilide Reduces Hospitalization in ICD Patients September 23, 2008:1076–83Patients who were hospitalized had a lower EF (mean
1% vs. 34%), higher NYHA functional class (62% in class
I/III vs. 47%), and more prevalent arrhythmic events (41%
trial fibrillation vs. 29%) at baseline, and were more likely
o have cardiomyopathy (61% vs. 50%) than those with no
ospitalization.
Discontinuation of blinded therapy for any reason oc-
urred in 40% of placebo patients versus 36% of patients
eceiving 75-mg azimilide, and in 35% of those receiving
25-mg azimilide. The incidence of patient withdrawal due
o adverse events was similar across the 3 groups. Torsades
e pointes (TdP) was observed in 1 patient on placebo, 2
eceiving 75-mg azimilide, and 3 receiving 125-mg azimil-
de. None were fatal, and all were terminated by the ICD
evice. The mean QTc intervals at baseline and post-
aseline (week 2) were 406 and 412, 403 and 432, and 409
nd 442 for placebo, 75-mg azimilide, and 125-mg azimil-
de, respectively.
There were a total of 20 (3%) deaths in this study, 7
3%) among placebo patients, 6 (3%) among patients on
5-mg azimilide, and 7 (4%) among patients on 125-mg
zimilide.
Table 4 shows the number of intensive care unit days per
atient/year, and Table 5 shows the number of in-hospital
ardiac procedures and treatments (injection or infusion) in
he 75-mg azimilide and placebo patients. More placebo-
Figure 3 Kaplan-Meier Cumulative Incidence of Cardiac
Arrhythmic-Related ED Visits and Hospitalizations
ATP  antitachycardia pacing; ED  emergency
department; ICD  implantable cardioverter-defibrillator.
elationship Between Defibrillator Therapy and Cardiac-Related ED
Table 3 Relationship Between Defibrillator Therapy and Cardiac
End Point
Patients who experienced shocks (n  213)
Patients who experienced both shocks plus symptomatic ATP (n  98)
Patients who experienced only symptomatic ATP (n  28)
Patients with no arrhythmic events (n  217)
Relative risk (RR) is calculated for each end point versus patients with no arrhythmic events; †F
ATP  antitachycardia pacing; other abbreviations as in Table 2.mreated patients required at least 1 in-hospital cardiac
rocedure than 75-mg azimilide-treated patients (90 vs. 60;
 0.001), including more in-hospital treatments (61 vs.
4; p  0.001).
We have not done a cost-benefit analysis since the
tudy was conducted in multiple countries and sites with
ifferent resource consumptions and costs. However, we
ave collected sufficient data on hospitalizations and
n-hospital procedures to allow a reasonable estimate of
he cost savings expected to be associated with azimilide
reatment for any particular jurisdiction or health care
ystem.
For example, the data in Table 4 show that over 1 year of
ollow-up there were 1,638 hospitalization days (7.65 days
er patient) observed among 214 placebo-assigned patients
nd 815 hospitalization days (3.70 days per patient) ob-
erved among 220 patients assigned to 75-mg azimilide.
his corresponds to a net reduction of 3.95 hospitalization
ays (including a reduction of approximately 1 intensive care
nit day) per patient per year.
Additional cost savings associated with reduced in-
ospital procedures are even more difficult to calculate, since
e did not record details of in-hospital tests or procedures.
able 5, however, allows some estimate of the resource
onsequences of the additional tests and procedures associ-
ted with the additional hospitalizations in the placebo
roup.
iscussion
he main findings of this study are that ED visits and
ospitalizations are very common in patients with an ICD
nd a prior history of VT or VF. Kaplan-Meier estimates
uggest that 383 of 1,000 patients with an ICD will have an
D visit or hospitalization every year. Azimilide, which
ignificantly reduces both the proportion of patients and the
umber of episodes of symptomatic arrhythmias treated by
TP or shock therapy (7), also substantially reduces the
umber of ED visits and hospitalizations, hospital days, and
n-hospital cardiac procedures.
Although ICDs clearly reduce mortality in patients at
igh risk for life-threatening ventricular arrhythmias (11–
4), patients with ICDs often receive appropriate, but
otentially unpleasant defibrillator therapies, which can
mpair quality of life (15–18). It would be anticipated that
s or Hospitalizations
ted ED Visits or Hospitalizations
ospitalization, n (%) RR* (95% CI) p Value†
135 (63.0%) 3.0 (2.3–3.9) 0.00001
64 (65.0%) 3.1 (2.3–4.1) 0.00001
12 (43.0%) 2.0 (1.2–3.3) 0.017
46 (21.0%)
act test.Visit
-Rela
Hany patients with symptomatic arrhythmias leading to
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September 23, 2008:1076–83 Azimilide Reduces Hospitalization in ICD PatientsCD therapy would seek unscheduled medical visits in an
D, and may be hospitalized if their physicians felt that
dditional investigations or treatments were necessary. The
ncidence of such ED visits and hospitalizations has not,
owever, been well documented in prior studies.
In the main SHIELD study, total ICD therapies for
ymptomatic arrhythmias (shocks plus symptomatic ATP)
ere reduced by 57%, and all-cause shocks reduced by 28%
n patients treated with 75-mg azimilide compared with
hat seen with placebo (7). The proportion of patients in
he SHIELD study who had shocks plus symptomatic
rrhythmias terminated by ATP and shocks alone was
8% and 53%, respectively, for placebo and 52% and 48%,
espectively, for 75-mg azimilide. Cardiac-related ED
isits or hospitalizations were reduced by 37% (HR: 0.63)
n the current study, and arrhythmic-related ED visits or
ospitalizations were even further reduced by 75-mg
zimilide (HR: 0.53): the proportion of patients visiting
he ED or hospitalized for cardiac reasons decreased from
1% to 35%.
The relatively large reduction in ED visits and hospi-
alizations by azimilide, taken together with the substan-
ial reduction in symptomatic arrhythmias terminated by
TP and the more modest decrease in shocks from the
CD, suggests that patients experiencing frequent symp-
omatic arrhythmias terminated by ATP are often seek-
ng medical intervention. In patients with symptomatic
rrhythmias terminated by ATP, but no shock therapy,
ardiac ED visits and hospitalizations were increased by
-fold, and arrhythmic-related ED visits and hospitaliza-
ion 4.2-fold, over the no-therapy group. Although we
ardiac-Related ED Visits or Hospitalizations and ICU Stays
Table 4 Cardiac-Related ED Visits or Hospitalizations and ICU S
ED Visits or Hospitalizatio
Category
Placebo (n  214)
Pt-Yrs  157
75-m
Total number of hospitalizations 211
Number of hospitalizations per patient 1.0
Number of total days 1,638
Number of total days per hospitalization 7.8
D  emergency department; ICU  intensive care unit.
Frequency of In-Hospital Procedures by Treatme
Table 5 Frequency of In-Hospital Procedures
Procedure Description
Coronary artery catheterization and/or biopsy
Diagnostic ultrasound of heart*
Electrophysiologic studies and ablation*
Injection or infusion of therapeutic or prophylactic substanc
Intubation of respiratory tract
Other nonoperative cardiac and vascular diagnostic procedu
Others
Pulmonary artery wedge*
Overall*Values are number of incidences (number of patients). *p  0.05 (3-way comid not record the specific reasons for nonarrhythmic
ospitalizations in the hospitalizations database, these
ere reduced by 43% (HR: 0.57) in the 75-mg azimilide
roup, an observation that may be related to the observed
eduction in CHF hospitalizations reported in the ad-
erse effects data logs.
Patients are particularly likely to be hospitalized if they
ave frequent clusters of arrhythmic events, so-called “elec-
rical storm.” Such patients are particularly prone to adverse
ffects on quality of life (19,20) and have been reported to
ave high short-term mortality (5,12,19,21–23). Treat-
ents that reduce the probability of “electrical storm” may
e expected to reduce hospitalization, but this has not been
ell documented in controlled clinical trials. Antiarrhyth-
ic therapy has previously been reported to reduce the
ikelihood of arrhythmias requiring ICD intervention. In a
andomized, open-label study of beta-blockers versus ami-
darone or sotalol, the antiarrhythmic drugs reduced shock
isk (amiodarone  beta-blockers vs. beta-blockers, HR:
.27, p  0.01, and sotalol vs. beta-blockers, HR: 0.61,
 0.06) (6). In a prior study, sotalol reduced the risk of
hocks versus placebo (HR: 0.61, p  0.001) (24). In the
HIELD study, approximately 1 of 4 patients experi-
nced at least 1 “electrical storm,” and 75-mg azimilide
ignificantly reduced storms of symptomatic arrhythmias
HR: 0.49, p  0.012) (5).
Patients who were hospitalized had a lower EF, higher
YHA functional class, and more prevalent arrhythmic
vents at baseline than those with no hospitalization. As
xpected, the majority (61%) of ED visits and hospitaliza-
ions in patients experiencing electrical storms occurred
missions ICU Admissions
ilde (n  220)
rs  167
Placebo (n  214)
Pt-Yrs  157
75-mg Azimilde (n  220)
Pt-Yrs  167
121 62 35
0.6 0.3 0.16
815 347 131
6.7 5.6 3.7
reatment
Placebo
(n  214)
75-mg Azimilide
(n  220)
125-mg Azimilide
(n  220)
18 (15) 11 (11) 13 (13)
72 (49) 27 (19) 37 (28)
17 (16) 9 (7) 10 (6)
555 (61) 349 (34) 368 (41)
11 (8) 4 (4) 7 (5)
47 (27) 16 (12) 41 (16)
49 (28) 29 (24) 40 (24)
36 (8) 2 (2) 2 (2)
805 (90) 447 (60) 518 (63)tays
ns Ad
g Azim
Pt-Ynt
by T
e*
resparisons between treatment groups).
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lose temporal relationship between an arrhythmic symp-
omatic event treated by ICD and the medical context.
Symptomatic arrhythmias and ICD shocks are a frequent
ause of ED/hospital visits. In the EURID (German ICD
egistry) study, 3,394 patients studied for 1 year experi-
nced 1,691 cardiac ED/hospital visits of which 61.3% were
rrhythmic (20). Additionally, several studies indicate that
CD therapies triggered by arrhythmias may result in
ncreased hospital visits. For example, the MADIT-II
Multicenter Automatic Defibrillator Implantation Trial-
I) and SCD-HeFT (Sudden Cardiac Death in Heart
ailure Trial) studies have shown that the time to first
ehospitalization was significantly shorter in patients with
CDs than the control patients (13,14). In addition, ICD-
elivered shocks or pacing may increase the risk of CHF,
hich was suggested by the MADIT-II and the DAVID
Dual Chamber and VVI Implantable Defibrillator) trials
13,25). Although the presence of an ICD is associated with
etter survival, it is also associated with an increased risk of
ehospitalization (26).
The key benefits of adjunctive antiarrhythmic treatment
ith azimilide in this study are the reductions in the
ymptomatic ventricular arrhythmic burden leading to re-
uctions in arrhythmia-related ED visits and hospitaliza-
ions. The potential risks regarding the use of this antiar-
hythmic agent are severe neutropenia and TdP, together
ith other minor side effects. Based on the SHIELD study,
pproximately 165 of 1,000 patients treated with azimilide
or 1 year may avoid arrhythmia-related ED visits and
ospitalizations whereas 5 of 1,000 (0.5%) patients may
xperience severe neutropenia, and 8 of 1,000 (0.8%) may
xperience TdP leading to a visit to a health care facility.
his study does not compare the potential strategy of
tarting adjunctive antiarrhythmic therapy at the time of
mplantation (for patients with no prior symptomatic VT or
F) versus the strategy of starting such drugs after docu-
ented VT/VF (before or after ICD implantation), but
oes suggest that reducing the burden of appropriate ther-
pies from the ICD has tangible benefits beyond patient
ymptoms and patient acceptance of the ICD.
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